|
|
Volumn 64, Issue SUPPL. 166, 2010, Pages 59-63
|
|
Immunomodulation for type 1 diabetes mellitus: Advanced technologies and treatments for diabetes
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AUTOANTIBODY;
C PEPTIDE;
ETANERCEPT;
GALECTIN 1;
GASTRIN;
GLUCAGON LIKE PEPTIDE 1;
GLUTAMATE DECARBOXYLASE;
HEMOGLOBIN A1C;
IMATINIB;
INSULIN;
INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY CANAKINUMAB;
PHOSPHOTRANSFERASE INHIBITOR;
PLX 647;
PROTEIN TYROSINE KINASE INHIBITOR;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RILONACEPT;
SUNITINIB;
TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTOR RECEPTOR 2;
UNCLASSIFIED DRUG;
AUTOIMMUNITY;
CD4+ CD25+ T LYMPHOCYTE;
CELL DESTRUCTION;
CLINICAL TRIAL;
ENDOCRINE DISEASE;
GENOTYPE;
HEMOGLOBIN BLOOD LEVEL;
HLA SYSTEM;
HUMAN;
IMMUNE RESPONSE;
IMMUNOMODULATION;
INSULIN DEPENDENT DIABETES MELLITUS;
INSULIN RELEASE;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
NONMYELOABLATIVE STEM CELL TRANSPLANTATION;
NOTE;
OLIGOSPERMIA;
PANCREAS ISLET BETA CELL;
PNEUMONIA;
PRIORITY JOURNAL;
REGULATORY T LYMPHOCYTE;
REMISSION;
T LYMPHOCYTE;
|
|
EID: 76749126708
PISSN: 13685031
EISSN: 17421241
Source Type: Journal
DOI: 10.1111/j.1742-1241.2009.02280.x Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
